Daratumumab and hyaluronidase is given as a subcutaneous injection, typically administered by a healthcare provider in a medical setting. Here’s how it is generally used:

• Injected Under the Skin: The injection is given into the fatty tissue just beneath the skin (usually in the thigh or abdomen).
• Schedule: The drug is given according to a schedule based on your treatment plan. Initially, you may receive the injection once a week, and then the schedule may change to once every two weeks or once a month, depending on how your body responds to the medication.
• Monitoring: You will be monitored during and after the injection for any signs of allergic reactions, such as swelling, rash, or difficulty breathing.

The medication works in two ways:

• Daratumumab: This is the primary active ingredient in the drug. It is a monoclonal antibody, meaning it is a type of protein designed to target a specific protein called CD38, found on the surface of multiple myeloma cells. By attaching to CD38, Daratumumab helps the immune system recognize and destroy the cancer cells.
• Hyaluronidase: This enzyme is added to help the medication spread more easily throughout the body. Hyaluronic acid is a substance naturally found in connective tissues, and it can create a barrier that slows the movement of the medication. Hyaluronidase breaks down this substance, allowing the Daratumumab to be absorbed faster and more effectively.

Together, Daratumumab and hyaluronidase work to improve the treatment of multiple myeloma by targeting and attacking the cancer cells while also enhancing the drug’s delivery throughout the body.

Like all medications, Daratumumab and hyaluronidase can cause side effects. Common side effects include:

• Infusion or Injection Reactions: These reactions are common, especially after the first dose. Symptoms can include fever, chills, fatigue, nausea, or headache. These symptoms usually go away after the first few doses.
• Infections: Because the medication affects the immune system, it can increase the risk of infections like respiratory infections, pneumonia, or urinary tract infections.
• Low Blood Cell Counts: The drug can affect your blood cells, causing low red blood cell counts (anemia), low white blood cell counts (increased risk of infections), or low platelets (increased risk of bleeding).

Serious Side Effects:

• Severe Allergic Reactions: Rarely, patients may experience severe allergic reactions, including difficulty breathing, rash, or swelling. If you have any of these symptoms, seek immediate medical attention.
• Pneumonia: There is an increased risk of lung infections like pneumonia, which can be serious.

Before starting Daratumumab and hyaluronidase, there are some important warnings and precautions to keep in mind:

• Allergic Reactions: Some patients may have allergic reactions to Daratumumab. Your healthcare provider will monitor you during and after the injection, especially during the first few doses.
• Infections: Since Daratumumab can affect your immune system, you may be more susceptible to infections. If you develop symptoms of an infection, such as fever or cough, inform your doctor right away.
• Liver or Kidney Problems: If you have a history of liver or kidney problems, tell your doctor, as your treatment may need to be adjusted.
• Pregnancy and Breastfeeding: Daratumumab and hyaluronidase should not be used during pregnancy unless absolutely necessary, and it is not recommended while breastfeeding.

Daratumumab and hyaluronidase can interact with other medications, so it’s important to tell your healthcare provider about any other treatments you are using. Some key interactions include:

• Other Immunosuppressive Drugs: Daratumumab works by stimulating the immune system to attack cancer cells. Using other immunosuppressive medications may reduce the effectiveness of the treatment or increase the risk of infections.
• Vaccines: Since Daratumumab affects the immune system, certain vaccines may not work as well. Live vaccines should generally be avoided during treatment, and you should discuss any upcoming vaccinations with your doctor.
• Infections: Daratumumab can increase the risk of infections because it can affect the immune system’s ability to fight off germs. If you are using other medications that also increase the risk of infection, the doctor may monitor you more closely.

Always consult your doctor before combining Daratumumab and hyaluronidase with other treatments.

Daratumumab and hyaluronidase is given as a subcutaneous injection, and the dosage will be determined by your doctor based on your condition and how well you respond to the treatment.

• Initial Dosing: The starting dose is usually higher, and it is given more frequently in the beginning.
• Maintenance Dosing: After the initial treatment period, the doses are spaced out, usually once every 2 weeks or once a month.

Daratumumab and hyaluronidase is available only by prescription and should be administered under the supervision of a healthcare provider. The medication is delivered in a clinical setting, and you should follow the prescribed treatment plan to achieve the best results.

1. What is Daratumumab and hyaluronidase combo used for?
   Treatment of multiple myeloma, similar to Daratumumab alone but delivered subcutaneously.

2. Why is hyaluronidase included with Daratumumab?
   Hyaluronidase helps increase the absorption of Daratumumab by breaking down tissue barriers, allowing for subcutaneous injection.

3. How is Daratumumab and hyaluronidase administered?
   By subcutaneous injection, usually in the abdomen.

4. What are the advantages of the combo over intravenous Daratumumab?
   Shorter administration time, improved convenience, and potentially fewer infusion-related reactions.

5. Are the side effects different from Daratumumab IV?
   Side effects are similar, but injection site reactions may be more common.

6. Is the combination as effective as intravenous Daratumumab?
   Yes, clinical studies show comparable efficacy.

7. What common side effects should I expect?
   Fatigue, nausea, injection site reactions, neutropenia, respiratory infections.

8. Can this combo cause allergic reactions?
   Yes, hypersensitivity reactions can occur and should be monitored.

9. Is premedication required for Daratumumab and hyaluronidase?
   Yes, to reduce injection and immune reactions (steroids, antihistamines, acetaminophen).

10. How often is Daratumumab and hyaluronidase given?
    Weekly initially, then less frequently (as per treatment protocol).

11. Can this combination be used in newly diagnosed multiple myeloma?
    Yes, often used in combination regimens for newly diagnosed or relapsed disease.

12. Does hyaluronidase have any therapeutic effects on its own?
    No, it mainly facilitates drug absorption.

13. Are there any contraindications?
    History of severe hypersensitivity to either component.

14. Is this combination FDA approved?
    Yes, the subcutaneous formulation is FDA-approved.

15. Can Daratumumab and hyaluronidase be used in patients with kidney issues?
    Yes, no dose adjustment is necessary for renal impairment.

16. Is the combination covered by insurance?
    Generally, yes, as part of multiple myeloma treatment coverage.

17. Can it be used with other myeloma treatments?
    Yes, often combined with other drugs like lenalidomide or bortezomib.

18. How should injection site reactions be managed?
    Cold compress, topical treatments, or analgesics may help.

19. Does hyaluronidase increase risk of infection?
    Not directly, but immune suppression from therapy increases infection risk.

20. Is there a generic combination available?
    No, currently it is available only as a branded combination (Darzalex Faspro).